Advertisement

Topics

Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD

11:41 EDT 10 Aug 2018 | Investing News Network

Gemphire Therapeutics (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver … Continued

The post Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD appeared first on Investing News Network.

Original Article: Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD

NEXT ARTICLE

More From BioPortfolio on "Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD"

Advertisement
Quick Search
Advertisement
Advertisement